1. Home
  2. CZNC vs INDP Comparison

CZNC vs INDP Comparison

Compare CZNC & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Citizens & Northern Corp

CZNC

Citizens & Northern Corp

HOLD

Current Price

$27.63

Market Cap

465.4M

Sector

Finance

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

SELL

Current Price

$3.20

Market Cap

438.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CZNC
INDP
Founded
1864
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
465.4M
438.4M
IPO Year
2009
2021

Fundamental Metrics

Financial Performance
Metric
CZNC
INDP
Price
$27.63
$3.20
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
46.6K
★ 434.4K
Earning Date
11-03-2026
11-11-2026
Dividend Yield
★ 4.20%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.81
N/A
Revenue
N/A
N/A
Revenue This Year
$38.42
N/A
Revenue Next Year
$4.97
N/A
P/E Ratio
$32.90
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.87
$0.92
52 Week High
$26.73
$5.96

Technical Indicators

Market Signals
Indicator
CZNC
INDP
Relative Strength Index (RSI) 76.41 57.84
Support Level $25.09 $2.05
Resistance Level N/A $3.75
Average True Range (ATR) 0.62 0.33
MACD 0.22 0.05
Stochastic Oscillator 100.00 92.43

Price Performance

Historical Comparison
CZNC
INDP

About CZNC Citizens & Northern Corp

Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: